Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Picks of the quarter -- Ignore unavailable to you. Want to Upgrade?

To: Elroy who wrote (4204)	9/5/2007 3:05:52 PM
From: Mike McFarland	Read Replies (2) \| Respond to of 20435

Thanks--I'll let the cash burn a hole through my pocket and spend it on HLCS. I had this in the last contest--but sequencing has been in the news, so I'll try it again. There is a nice writeup here: seekingalpha.com Boy, when you see a bright kid do a nice writeup, it sure makes you feel old and stupid <g>. This might be a good point to be wary about--he writes Helicos is keeping entirely mum about what I believe to be its Achilles heel ... accuracy. Still, 454 was bought by Roche and Solexa ended up with ILMN, so what the heck. Sequenom has been doing well too lately. Helicos is very thinly traded, up a little today, which is annoying for putting it in the contest. Here is a recent article worth reading, as I said genomics is in the news again--it was all the rage five years ago and so maybe this is an aftershock, heh. Venter again: technologyreview.com SNP stocks did well for a time, Orchid, others that I've forgotten or tried to forget were bought out. An interesting story I was reminded of today was Genaissance, which ended up at CLDA. Clinical Data is one I ought to have stayed with instead of batting at groundhogs (I owned gnsc for a time).